Belpointe Asset Management LLC Abb Vie Inc. Transaction History

Belpointe Asset Management LLC

$1.24 Billion
Q1 2024

A detailed history of Belpointe Asset Management LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Belpointe Asset Management LLC holds 36,698 shares of ABBV stock, worth $6.09 Million. This represents 0.54% of its overall portfolio holdings.

Number of Shares

36,698

Previous 34,550 6.22%

Holding current value

$6.09 Million

Previous $5.35 Million 24.8%

% of portfolio

0.54%

Previous 0.51%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 08, 2024	BUY	$159.82 - $182.1 $343,293 - $391,150	2,148 Added 6.22%	36,698 $6.68 Million
Q4 2023 Feb 13, 2024	BUY	$137.6 - $154.97 $55,452 - $62,452	403 Added 1.18%	34,550 $5.35 Million
Q3 2023 Nov 15, 2023	BUY	$133.59 - $154.65 $129,715 - $150,165	971 Added 2.93%	34,147 $5.09 Million
Q2 2023 Aug 14, 2023	SELL	$132.51 - $164.9 $3.38 Million - $4.2 Million	-25,476 Reduced 43.44%	33,176 $4.47 Million
Q1 2023 May 15, 2023	SELL	$144.61 - $166.54 $342,147 - $394,033	-2,366 Reduced 3.88%	58,652 $9.35 Million

Q4 2022 Feb 08, 2023	BUY	$138.31 - $165.87 $664,856 - $797,337	4,807 Added 8.55%	61,018 $9.87 Million
Q3 2022 Nov 14, 2022	BUY	$134.21 - $153.93 $1.4 Million - $1.6 Million	10,423 Added 22.76%	56,211 $7.54 Million
Q2 2022 Aug 02, 2022	SELL	$137.62 - $174.96 $1.36 Million - $1.73 Million	-9,900 Reduced 17.78%	45,788 $7.01 Million
Q1 2022 Apr 28, 2022	SELL	$131.98 - $163.75 $1.53 Million - $1.9 Million	-11,610 Reduced 17.25%	55,688 $9.03 Million
Q4 2021 Feb 15, 2022	BUY	$107.43 - $135.93 $158,351 - $200,360	1,474 Added 2.24%	67,298 $9.11 Million
Q3 2021 Nov 15, 2021	BUY	$106.4 - $120.78 $1.29 Million - $1.47 Million	12,164 Added 22.67%	65,824 $7.1 Million
Q2 2021 Aug 09, 2021	BUY	$105.21 - $117.21 $277,964 - $309,668	2,642 Added 5.18%	53,660 $6.04 Million
Q1 2021 May 14, 2021	SELL	$102.3 - $112.62 $669,758 - $737,323	-6,547 Reduced 11.37%	51,018 $5.52 Million
Q4 2020 Feb 16, 2021	BUY	$80.49 - $108.67 $253,141 - $341,767	3,145 Added 5.78%	57,565 $6.17 Million
Q3 2020 Nov 13, 2020	SELL	$85.91 - $100.83 $2.73 Million - $3.2 Million	-31,762 Reduced 50.22%	31,487 $2.4 Million
Q3 2020 Nov 13, 2020	BUY	$85.91 - $100.83 $1.97 Million - $2.31 Million	22,933 Added 72.83%	54,420 $4.77 Million
Q2 2020 Jul 20, 2020	BUY	$73.37 - $98.18 $2.33 Million - $3.12 Million	31,762 Added 100.87%	63,249 $6.21 Million
Q1 2020 Jul 20, 2020	SELL	$64.5 - $97.79 $119,196 - $180,715	-1,848 Reduced 5.54%	31,487 $2.4 Million
Q4 2019 Feb 18, 2020	BUY	$72.13 - $90.25 $432,130 - $540,687	5,991 Added 21.91%	33,335 $2.95 Million
Q3 2019 Jan 16, 2020	BUY	$62.98 - $75.72 $226,035 - $271,759	3,589 Added 15.11%	27,344 $2.07 Million
Q2 2019 Nov 22, 2019	SELL	$65.7 - $83.98 $39,222 - $50,136	-597 Reduced 2.45%	23,755 $0
Q1 2019 Jun 11, 2019	BUY	$77.14 - $90.79 $7,945 - $9,351	103 Added 0.42%	24,352 $1.96 Million
Q4 2018 Mar 06, 2019	BUY	$77.85 - $96.01 $338,024 - $416,875	4,342 Added 21.81%	24,249 $2.24 Million
Q3 2018 Nov 23, 2018	SELL	$88.91 - $98.84 $83,842 - $93,206	-943 Reduced 4.52%	19,907 $1.88 Million
Q2 2018 Aug 06, 2018	SELL	$89.78 - $106.23 $112,045 - $132,575	-1,248 Reduced 5.65%	20,850 $1.93 Million
Q1 2018 Aug 06, 2018	SELL	$92.01 - $123.21 $708,661 - $948,963	-7,702 Reduced 25.85%	22,098 $2.09 Million
Q4 2017 Feb 15, 2018	BUY	$89.56 - $98.21 $492,848 - $540,449	5,503 Added 22.65%	29,800 $2.88 Million
Q3 2017 Nov 16, 2017	BUY	$69.85 - $89.22 $1.7 Million - $2.17 Million	24,297	24,297 $2.16 Million

Others Institutions Holding ABBV

# of Institutions

3,652

Shares Held

1.24B

Call Options Held

15.5M

Put Options Held

11.6M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $293B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Belpointe Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Belpointe Asset Management LLC with notifications on news.

Account

Belpointe Asset Management LLC Abb Vie Inc. Transaction History